Ultra-Early Hematoma Expansion Is Associated With Ongoing Hematoma Growth and Poor Functional Outcome
Authors:
- Chloe A. MutimerCMChloe A. Mutimer
- Teddy Y. WuTWTeddy Y. Wu
- Henry ZhaoHZHenry Zhao
- Leonid ChurilovLCLeonid Churilov
- Bruce C.V. CampbellBCBruce C.V. Campbell
- Andrew CheungACAndrew Cheung
- Atte MeretojaAMAtte Meretoja
- Timothy J. KleinigTKTimothy J. Kleinig
- Philip M. ChoiPCPhilip M. Choi
- Geoffrey C. CloudGCGeoffrey C. Cloud
- Rohan GrimleyRGRohan Grimley
- 1 April 2025
- journal article
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (4) , 838-847
Abstract
BACKGROUND: There are limited data on ultra-early hematoma growth dynamics and their clinical impact in primary intracerebral hemorrhage (ICH). We aimed to estimate the incidence of hematoma expansion within the hyperacute period of ICH, describe hematoma dynamics over time, investigate the associations between ultra-early hematoma expansion and clinical outcomes after ICH, and assess the effect of tranexamic acid on ultra-early hematoma expansion. METHODS: We performed a preplanned secondary analysis of the STOP-MSU trial (Stopping Intracerebral Hemorrhage With Tranexamic Acid for Hyperacute Onset Presentation Including Mobile Stroke Units), which compared tranexamic acid with placebo in 201 patients with primary ICH presenting within 2 hours of symptom onset. Repeat computed tomography imaging ≈1 hour after treatment commencement was encouraged (ultra-early reimaging), and patients with this imaging were included in this descriptive study. Imaging analyses were separated into the following time epochs: baseline—the period from onset-to-baseline imaging; ultra-early—the period from baseline imaging to ultra-early reimaging; and interval—the period from ultra-early reimaging to 24-hour reimaging. Hematoma expansion was defined as a ≥33% or ≥6 mL increase from baseline, and functional outcomes were assessed at 90 days (poor functional outcome defined as modified Rankin Scale score of 3–6) using unadjusted logistic regression models. RESULTS: We included 105 patients who had ultra-early reimaging (median age, 66 years; 40% female). Median onset-to-baseline imaging time was 74 minutes (interquartile range, 56–87 minutes), and baseline-to-ultra-early reimaging time was 95 minutes (interquartile range, 74–132 minutes). Forty-one patients (39%) had ultra-early hematoma expansion. These patients had larger baseline hematomas (15.9 mL versus 9.1 mL, P =0.03) compared with those with no early hematoma expansion. Hematoma growth rate declined over time (clustered median regression P P P P P =0.65). CONCLUSIONS: In patients with ICH presenting within 2 hours of symptom onset, most hematoma growth occurs in the ultra-early period. The presence of ultra-early hematoma expansion is associated with ongoing hematoma growth, poor functional outcomes, and mortality and represents a target for therapeutic intervention.Keywords
All Related Versions
Funding Information
- UNIMELB | Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne
This publication has 25 references indexed in Scilit:
- Tranexamic acid versus placebo in individuals with intracerebral haemorrhage treated within 2 h of symptom onset (STOP-MSU): an international, double-blind, randomised, phase 2 trialThe Lancet Neurology, 2024
- Time to Anticoagulation Reversal and Outcomes After Intracerebral HemorrhageJAMA Neurology, 2024
- The third Intensive Care Bundle with Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT3): an international, stepped wedge cluster randomised controlled trialThe Lancet, 2023
- Let the question determine the methods: descriptive epidemiology done rightBritish Journal of Cancer, 2020
- Absolute risk and predictors of the growth of acute spontaneous intracerebral haemorrhage: a systematic review and meta-analysis of individual patient dataThe Lancet Neurology, 2018
- Software output from semi-automated planimetry can underestimate intracerebral haemorrhage and peri-haematomal oedema volumes by up to 41 %Neuroradiology, 2016
- Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trialThe Lancet Neurology, 2016
- Anticoagulant Reversal, Blood Pressure Levels, and Anticoagulant Resumption in Patients With Anticoagulation-Related Intracerebral HemorrhageJAMA, 2015
- Modeling the Pattern of Contrast Extravasation in Acute Intracerebral Hemorrhage Using Dynamic Contrast-Enhanced MRNeurocritical Care, 2014
- Intracerebral haemorrhageThe Lancet, 2009